{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:55:31Z","timestamp":1789152931034,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12282-026-01851-6","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:07:13Z","timestamp":1775552833000},"page":"744-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low-progesterone receptor expression predicts nodal pathological complete response after neoadjuvant chemotherapy in premenopausal patients with ER-positive\/HER2-negative breast cancer"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1406-0760","authenticated-orcid":false,"given":"Naoko","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kuwayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"1851_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","volume":"11","author":"KS \u0f09Albain","year":"2010","unstructured":"Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy:a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55\u201365.","journal-title":"Lancet Oncol"},{"key":"1851_CR2","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/annonc\/mdu118","volume":"25","author":"H \u0f09Bonnefoi","year":"2014","unstructured":"Bonnefoi H, Litiere S, Piccart M, et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994\/BIG 1\u2009\u2013\u200900 phase lll trial. Ann Oncol. 2014;25:1128\u201336.","journal-title":"Ann Oncol"},{"key":"1851_CR3","doi-asserted-by":"publisher","first-page":"e6930","DOI":"10.1002\/cam4.6930","volume":"13","author":"G \u0f09Houvenaeghel","year":"2024","unstructured":"Houvenaeghel G, de Nonneville A, Cohen M, et al. Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival. Cancer Med. 2024;13:e6930.","journal-title":"Cancer Med"},{"key":"1851_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-023-07152-2","volume":"203","author":"D \u0f09Moldoveanu","year":"2024","unstructured":"Moldoveanu D, Hoskin TL, Day CN, et al. Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+\/HER2- breast cancer. Breast Cancer Res Treat. 2024;203:419\u201328.","journal-title":"Breast Cancer Res Treat"},{"key":"1851_CR5","doi-asserted-by":"publisher","first-page":"1184021","DOI":"10.3389\/fonc.2023.1184021","volume":"9","author":"A \u0f09Garcia-Tejedor","year":"2023","unstructured":"Garcia-Tejedor A, Ortega-Exposito C, Salinas S, et al. Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial). Front Oncol. 2023;9:1184021.","journal-title":"Front Oncol"},{"key":"1851_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/tbcr-24-45","volume":"6","author":"A \u0f09Fancellu","year":"2025","unstructured":"Fancellu A, Giuliani G, Mulas S, et al. De-escalation of axillary treatment in early breast cancer-a narrative review of current trials. Transl Breast Cancer Res. 2025;6:5.","journal-title":"Transl Breast Cancer Res"},{"key":"1851_CR7","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1245\/s10434-022-11367-w","volume":"29","author":"FC \u0f09Verdial","year":"2022","unstructured":"Verdial FC, Mamtani A, Pawloski KR, et al. The effect of age on outcomes after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2022;29:3810\u20139.","journal-title":"Ann Surg Oncol"},{"key":"1851_CR8","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.1245\/s10434-022-11871-z","volume":"29","author":"JC \u0f09Boughey","year":"2022","unstructured":"Boughey JC, Hoskin T, Goetz MP. Neoadjuvant chemotherapy and nodal response rates in luminal breast cancer: effects of age and tumor Ki67. Ann Surg Oncol. 2022;29:5747\u201356.","journal-title":"Ann Surg Oncol"},{"key":"1851_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-11-2599","volume":"18","author":"HA \u0f09Azim Jr","year":"2012","unstructured":"Azim HA Jr, Michiels S, Bedard PL, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012;18:1341\u201351.","journal-title":"Clin Cancer Res"},{"key":"1851_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1055\/s-0039-3400457","volume":"41","author":"LR \u0f09da Silva","year":"2019","unstructured":"da Silva LR, Vargas RF, Shinzato JY, et al. Association of menopausal status, expression of progesterone receptor and Ki67 to the clinical response to neoadjuvant chemotherapy in luminal breast cancer. Rev Bras Ginecol Obstet. 2019;41:710\u20137.","journal-title":"Rev Bras Ginecol Obstet"},{"key":"1851_CR11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/jso.26096","volume":"122","author":"MR \u0f09Boland","year":"2020","unstructured":"Boland MR, Ryan EJ, Nugent T, et al. Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer patients. J Surg Oncol. 2020;122:861\u20138.","journal-title":"J Surg Oncol"},{"key":"1851_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.4048\/jbc.2019.22.e35","volume":"22","author":"HS \u0f09Kim","year":"2019","unstructured":"Kim HS, Yoo TK, Park WC, et al. Potential benefits of neoadjuvant chemotherapy in clinically node-positive luminal subtype breast cancer. J Breast Cancer. 2019;22:412\u201324.","journal-title":"J Breast Cancer"},{"key":"1851_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2147\/DDDT.S336643","volume":"16","author":"Z \u0f09Li","year":"2022","unstructured":"Li Z, Wei H, Li S, et al. The role of progesterone receptors in breast cancer. Drug Des Devel Ther. 2022;16:305\u201314.","journal-title":"Drug Des Devel Ther"},{"key":"1851_CR14","doi-asserted-by":"publisher","first-page":"813462","DOI":"10.3389\/fonc.2022.813462","volume":"12","author":"A \u0f09Diana","year":"2022","unstructured":"Diana A, Carlino F, Buono G, et al. Prognostic relevance of progesterone receptor levels in early luminal-like HER2 negative breast cancer subtypes: a retrospective analysis. Front Oncol. 2022;12:813462.","journal-title":"Front Oncol"},{"key":"1851_CR15","doi-asserted-by":"publisher","first-page":"175883592513428","DOI":"10.1177\/17588359251342874","volume":"17","author":"D \u0f09Quiroga","year":"2025","unstructured":"Quiroga D, Pei C, Stephens JA, et al. Impact of low hormone receptor expression on neoadjuvant chemotherapy response and patterns of care in non-metastatic HER2-negative breast cancer: a US National Cancer Database analysis. Ther Adv Med Oncol. 2025;17:17588359251342874.","journal-title":"Ther Adv Med Oncol"},{"key":"1851_CR16","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1007\/s12094-024-03777-x","volume":"27","author":"C \u0f09Berkel","year":"2025","unstructured":"Berkel C. Menopausal status-dependent alterations in the transcript levels of genes encoding ER\u03b1, ER\u03b2, PR and HER2 in breast tumors with different receptor status. Clin Trans Oncol. 2025;27:2441\u201352.","journal-title":"Clin Trans Oncol"},{"key":"1851_CR17","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2013.49.4062","volume":"31","author":"Y \u0f09Yamamoto","year":"2013","unstructured":"Yamamoto Y, Yamamoto-Ibusuki M, Iwase H. Menopausal status should be taken into consideration for patients with luminal a breast cancer in terms of the effect of differential biology on prognosis. J Clin Oncol. 2013;31:2516.","journal-title":"J Clin Oncol"},{"key":"1851_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000537874","volume":"69","author":"G \u0f09Akdag","year":"2024","unstructured":"Akdag G, Yildirim S, Dogan A, et al. Neoadjuvant chemotherapy and pathologic complete response in HR+\/HER2- breast cancer: impact of tumor Ki67 and ER status. Chemotherapy. 2024;69:141\u20139.","journal-title":"Chemotherapy"},{"key":"1851_CR19","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","volume":"25","author":"A \u0f09Lucci","year":"2007","unstructured":"Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657\u201363.","journal-title":"J Clin Oncol"},{"key":"1851_CR20","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M \u0f09Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS):a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303\u201310.","journal-title":"Lancet Oncol"},{"key":"1851_CR21","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS \u0f09Caudle","year":"2016","unstructured":"Caudle AS, Yang W, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072\u20138.","journal-title":"J Clin Oncol"},{"key":"1851_CR22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/jamaoncol.2024.0578","volume":"10","author":"G \u0f09Montagna","year":"2024","unstructured":"Montagna G, Mrdutt MM, Sun SX, et al. Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncol. 2024;10:793\u20138.","journal-title":"JAMA Oncol"},{"key":"1851_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamasurg.2023.1772","volume":"158","author":"S \u0f09Kuemmel","year":"2023","unstructured":"Kuemmel S, Heil J, Bruzas S, et al. Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer. JAMA Surg. 2023;158:807\u201315.","journal-title":"JAMA Surg"},{"key":"1851_CR24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12957-022-02787-9","volume":"29","author":"D \u0f09Guan","year":"2022","unstructured":"Guan D, Jie Q, Wu Y, et al. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor-2-negative breast cancer: a multicenter, retrospective study in China. World J Surg Oncol. 2022;29:326.","journal-title":"World J Surg Oncol"},{"key":"1851_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","volume":"260","author":"JC \u0f09Boughey","year":"2014","unstructured":"Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260:608\u201314.","journal-title":"Ann Surg"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01851-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01851-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01851-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:27:41Z","timestamp":1777382861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01851-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1851"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01851-6","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Masakazu Toi has received honoraria from Daiichi Sankyo, Eli Lilly, and AstraZeneca; and research funding from Taiho, AstraZeneca, Kyowa-Kirin, Shimadzu, Astellas, AFI Technology, Yakult, and Luxonus, outside the submitted work. He also serves in unpaid leadership roles in breast cancer research groups including JBCRG and KBCRN. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board of Komagome Hospital (Approval No. 3513). Because this was a retrospective study using existing clinical data, written informed consent was not required. Instead, information about the study was disclosed on the hospital website, and patients were given the opportunity to opt out.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}